6547.TWO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 01:30):

Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally...

Stats
Today's Volume	1.67M
Average Volume	1.43M
Market Cap	15.94B
EPS	TWD0 ( 2024-03-15 )
Next earnings date	( TWD0 ) 2024-05-02
Last Dividend	TWD0 ( N/A )
Next Dividend	TWD0 ( N/A )
P/E	-13.74
ATR14	TWD0.0410 (0.08%)

Volume Correlation

Long: -0.14 (neutral)

Short: -0.76 (moderate negative)

Signal:(39.773) Neutral

Medigen Vaccine Biologics Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Medigen Vaccine Biologics Correlation - Currency/Commodity

-0.24
( neutral )

-0.41
( neutral )

0.00
( neutral )

0.58
( weak )

-0.45
( neutral )

-0.76
( moderate negative )

Medigen Vaccine Biologics Financials

Annual	2023
Revenue:	TWD389.62M
Gross Profit:	TWD221.15M (56.76 %)
EPS:	TWD-3.53

Q4	2023
Revenue:	TWD171.34M
Gross Profit:	TWD116.85M (68.20 %)
EPS:	TWD-1.770

Q3	2023
Revenue:	TWD218.29M
Gross Profit:	TWD111.33M (51.00 %)
EPS:	TWD-0.160

Q2	2023
Revenue:	TWD0
Gross Profit:	TWD-32.77M (0.00 %)
EPS:	TWD-0.960

Financial Reports:

No articles found.

Medigen Vaccine Biologics

Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19- severe special infectious pneumonia. Medigen Vaccine Biologics Corporation was founded in 2012 and is based in Taipei, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.